RxDoctor Payments Data

Laura Balmain, MD

Gastroenterology · Texarkana, TXNPI 1386642692

Payments from drug & device makers

$5,907in general payments, 2019–2025

Across 400 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$598
  • Pfizer$587
  • Gilead$543
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
  • Takeda Pharmaceuticals U.S.A., Inc.$405
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$5,76098%
  • Education$1322%
  • Gifts$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,907 in reported general payments places this provider in the 60th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$550,771
Medicare patients
745
Services billed
10,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab18$498,365
CreonLipase/Protease/Amylase88$132,398
LinzessLinaclotide107$82,922
XifaxanRifaximin13$48,580
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates312$19,746
Dexlansoprazole DrDexlansoprazole49$15,224
MovantikNaloxegol Oxalate20$10,853
Sucralfate66$10,310
Esomeprazole Magnesium92$7,835
Pantoprazole Sodium554$6,726
Mesalamine11$6,367
Colesevelam Hcl49$6,038
CholestyramineCholestyramine (With Sugar)61$3,525
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,911
Omeprazole180$2,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$598$498,36518 claims
AbbVieCreon, Linzess$2,147$215,320195 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$463$50,90030 claims
Redhill Biopharma Inc.Movantik$36$10,85320 claims
Braintree Laboratories, Inc.Sutab$57$2,91118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →